Major Pulmonary Embolism: Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism

Kenneth E. Wood

*Chest* 2002;121:877-905
DOI: 10.1378/chest.121.3.877

This information is current as of February 6, 2007

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://www.chestjournal.org/cgi/content/full/121/3/877
Major Pulmonary Embolism (PE) results whenever the combination of embolism size and underlying cardiopulmonary status interact to produce hemodynamic instability. Physical findings and standard data crudely estimate the severity of the embolic event in patients without prior cardiopulmonary disease (CPD) but are unreliable indicators in patients with prior CPD. In either case, the presence of shock defines a threefold to sevenfold increase in mortality, with a majority of deaths occurring within 1 h of presentation. A rapid integration of historical information and physical findings with readily available laboratory data and a structured physiologic approach to diagnosis and resuscitation are necessary for optimal therapeutics in this “golden hour.” Echocardiography is ideal because it is transportable, and is capable of differentiating shock states and recognizing the characteristic features of PE. Spiral CT scanning is evolving to replace angiography as a confirmatory study in this population. Thrombolytic therapy is acknowledged as the treatment of choice, with embolectomy reserved for those in whom thrombolysis is contraindicated.

Key words: echocardiogram; embolectomy; hemodynamics; pulmonary embolism; shock; thrombolytic therapy

Abbreviations: aPTT = activated partial thromboplastin time; CO = cardiac output; CPD = cardiopulmonary disease; CPR = cardiopulmonary resuscitation; CPP = coronary perfusion pressure; CXR = chest radiograph; DVT = deep venous thrombosis; ECHO = echocardiography; ICOPER = International Cooperative Pulmonary Embolism Registry; IVC = inferior vena cava; LV = left ventricular; MAP = mean arterial pressure; MAPPET = Management Strategy and Prognosis of Pulmonary Embolism Registry; mPAP = mean pulmonary artery pressure; MPE = major pulmonary embolism; NE = norepinephrine; PA = pulmonary artery; PA(a–O₂) = alveolar-arterial oxygen pressure difference; PAP = pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure; PE = pulmonary embolism; PEA = pulseless electrical activity; PIOPED = Prospective Investigation of Pulmonary Embolism Diagnosis; PVC = pressure venous capacitance; PVR = pulmonary vascular resistance; RA = right atrium; RAP = right atrial pressure; RBBB = right bundle branch block; rt-PA = recombinant tissue plasminogen activator; RV = right ventricle, ventricular; RVEDP = right ventricular end-diastolic pressure; SVO₂ = systemic venous oxygen saturation; TEE = transesophageal echocardiography; TR = tricuspid regurgitation; TTE = transthoracic echocardiography; UPET = Urokinase Streptokinase Pulmonary Embolism Trial; UK = urokinase; USPET = Urokinase Streptokinase Pulmonary Embolism Trial; Vd/Vt = physiologic dead space ventilation; V/Q = ventilation/perfusion ratio; VR = venous return

Venous thrombosis is always a severe disease and is often fatal, because fragments of the thrombi may detach and occlude branches of the pulmonary artery... the occlusion of the main branches of the pulmonary artery causes a striking rise of the blood pressure in these vessels. This rise—which the right heart must fight in order to ensure circulation—may sometimes lead to cardiac arrest.

- Picot 1884
- Lecous de Clinique Médicale

For related article see page 806
autopsy series in which the incidence of PE directly causing, contributing, or accompanying death in hospitalized patients has remained remarkably constant at about 15% over the last 40 years. Similarly, the antemortem diagnosis of fatal PE has not changed appreciably over the same time interval and remains fixed at approximately 30%. Although two large contemporary observational studies that have included patients with massive PE or that have focused on hemodynamically significant PE have reported significantly higher mortality rates. In the International Cooperative Pulmonary Embolism Registry (ICOPER), the overall three month mortality for all PE patients was 17.4%. The in-hospital mortality rate for patients in the Management Strategies and Determinants of Outcome in Acute Pulmonary Embolism Trial (MAPPET) rose to 31% in those patients presenting with hemodynamic instability. The mortality rate directly ascribed to PE was 45% in the ICOPER and 91% in the MAPPET. Thus, PE remains common, underdiagnosed, and lethal.

In fatal cases, it has long been recognized that two thirds of those patients will die within 1 h of presentation and that anatomically massive PE will only account for one half of those deaths, with the remainder attributed to smaller submassive or recurrent emboli. Although life-threatening PE traditionally has been equated with anatomically massive PE (defined as a > 50% obstruction of the pulmonary vasculature or the occlusion of two or more lobar arteries), it seems reasonable to propose that the outcome from PE is a function of both the size of the embolus and the underlying cardiopulmonary function. A massive embolus in a patient with adequate cardiopulmonary reserve and a submassive embolus in a patient with prior cardiopulmonary disease (CPD) and poor reserve may manifest similar hemodynamic and clinical outcomes. The length of time from the occurrence of a single embolus or multiple recurrent emboli impacting the cardiovascular system to the accrual of physiologic data is often unknown. When that time period is appreciated, it appears that the magnitude of the cardiovascular abnormalities are diminished with time, probably as a consequence of the intrinsic fibrinolytic system and mechanical fracturing of the embolus. Thus, the length of time to presentation

![Outcomes in Pulmonary Embolism](image)

**Figure 1.** The relationship of severity and mortality in patients with MPE.
can add another dimension to the physiolog and outcome characterization.\textsuperscript{32,37,38} In an attempt to integrate embolus size and cardiopulmonary function to reconcile clinical outcome, it has been suggested that the term major be used to define any combination of embolus size and cardiopulmonary function that results in a hemodynamically significant event.\textsuperscript{28} Figure 1 depicts the proposed relationship between mortality and severity as characterized by a combination of embolus size and cardiopulmonary status. Progressive increments in severity are associated with a relatively low constant mortality outcome, provided that therapeutic anticoagulation is achieved. From reported series,\textsuperscript{13,35,39} it is evident that the combination of embolus size and the cardiopulmonary function necessary to produce shock is associated with a mortality rate of approximately 30%. A minimal increase in severity produces cardiac arrest, which has a mortality rate of at least 70% in reported series.\textsuperscript{13,40} However, the exact combination of embolus size and cardiopulmonary status that produces the mortality inflection point remains elusive. The presence of right ventricular (RV) dysfunction in normotensive patients with PE has been proposed to signify this critical point, although this remains controversial as a substantial number of PE patients will have RV dysfunction and low mortality rates.\textsuperscript{41} Reconciling the clinical predictors necessary to establish this critical inflexion is crucial because it will define the threshold at which patients are deemed to be at sufficient risk with conventional therapy to justify the additional risk and potential benefits of more aggressive and costly therapies. Although it is appealing to define major PE (MPE) as a function of the mortality inflexion point characterized by incipient hypotension, a more pragmatic definition is required because the clinical identifiers of the inflexion point are unknown at this time. For the purpose of this review, MPE is defined by the clinical spectrum ranging from hypotension to cardiac arrest. Syncope most likely represents an intermediary position, as the failure to regain consciousness inevitably results in cardiac arrest and those patients who recover consciousness have a high incidence of hypotension.\textsuperscript{42}

Hemodynamic instability secondary to RV failure as a function of embolism size and underlying cardiopulmonary status is thought to be a more accurate indicator of the magnitude of PE than the degree of angiographic obstruction.\textsuperscript{33,37,39} The presence of hemodynamic decompensation or shock is associated with an approximate threefold to sevenfold increase in mortality, which is best exemplified in the original observation from the Urokinase Pulmonary Embolism Trial (UPET)\textsuperscript{38} [mortality, 36% vs 5%, respectively], was confirmed in the series by Alpert et al\textsuperscript{39} (mortality, 25% vs 5%, respectively), and was contemporarily reconfirmed in the ICOPER study\textsuperscript{12} (mortality, 58.3% vs 15.1%, respectively). Interestingly, the mortality rate in the UPET was slightly higher for submassive PE than for massive PE (mortality, 9.8% vs 6.7%, respectively), further illustrating the relationships among embolus size, cardiopulmonary status, and outcome. Data from the largest observational study\textsuperscript{12} of PE have reconfirmed systolic arterial hypotension as the most significant prognostic indicator of outcome. Thus, the presence of shock or hemodynamic instability clearly provides an early and readily available discriminator between potential survivors and nonsurvivors. The preceding provides the rationale to devise a physiologic approach to the diagnosis and management of MPE.

As the physiologic response to MPE within the first hour will very likely determine the survival and availability of patients for subsequent studies, survivors of MPE, particularly those who have been entered into clinical trials, represent a selected group. There are no randomized prospective trials designed to study MPE, and it is not likely that any will be undertaken. Hemodynamic instability, impending death, and contraindications to thrombotic therapy are exclusion criteria in many studies\textsuperscript{10,11,43–48} and undoubtedly preclude a realistic reporting of MPE. Observational case series with variability in operational definitions that rarely integrate hemodynamics, cardiopulmonary status, or embolism size with outcome provide the largest data source for MPE. Cases of anatomically massive PE dominate this literature; however, it is crucial to recognize that this is not equitable to patients with MPE, as only a minority of patients with anatomically massive PE will have hemodynamic instability.\textsuperscript{35,39} Consequently, high-level, evidenced-based recommendations are not available. The purpose of this article is to provide a structured physiologic approach to diagnosis, and to resuscitative and therapeutic strategies as well as a discussion of issues specifically germane to MPE. Similar to the “golden hour” of trauma, myocardial infarction, and stroke, there exists a golden hour of MPE during which a timely approach to diagnosis and therapy potentially can impact outcome.

**Circulatory Model.**

The care of the critically ill hemodynamically unstable patient often proceeds along the following two parallel paths: physiologic resuscitation and differential diagnosis investigation. Frequently, the initial physiologic characterization and the subsequent physiologic response to therapy contribute to estab-
lishing the definitive diagnosis and initiating optimal treatment. Accordingly, the utilization of a universally applicable physiologic model of the circulation that allows for the expeditious application of resuscitative and diagnostic strategies is beneficial. This is particularly pertinent to MPE, given the acknowledged difficulty in deciphering the process, the potential for rapid lethality, and controversies in treatment. A fundamental understanding and review of basic hemodynamic principles is imperative to appreciate the pathophysiologic alterations induced by various disease states. Utilizing Poiseuille’s law, conventional hemodynamics conceptualize the circulatory system as an open cylindrical conduit with cardiac output \((CO)\) defined as a function of pressure gradients (mean arterial pressure \([MAP]\) – right atrial pressure \([RAP]\)) against resistance (Fig 2). However, recognizing that \(CO\) is pulsatile, it is useful to devise a model that includes a hydraulic pump.

Figure 3 illustrates a three-compartment circulatory model that conceptualizes the circulatory system as a hydraulic pump composed of a right heart pump linked in series to a left heart pump. As a consequence of this serial hydraulic alignment, \(CO\) cannot exceed venous return \((VR)\) and vice versa. In other words, left heart output cannot exceed right heart output, which allows for the conceptualization of both pumps as a single hydraulic unit. The hydraulic pump is primed with volume from the venous capacitance bed \([\text{ie, the volume reservoir}]\) and empties into the arterial impedance bed \((\text{ie, the resistive element})\). Guyton et al\(^4\) recognized that the pressure gradient for \(VR\) is the ratio of pressure in the venous capacitance bed \((\text{PVC})\) to the RAP

\[ \text{VR} = \text{PVC} - \text{RAP}, \]

thus establishing the integral role of the right atrium \((RA)\) as a coupler of the venous system and cardiac hydraulic circulation. The graphic solution of this observation is depicted in Figure 3. PVC is a function of venous volume and vascular tone, which must exceed the RAP to maintain VR. The RAP provides not only an assessment of the pressure in the right heart but an indirect gauge of the pressure in the venous capacitance system. Thus, the circulatory system can be defined as a three-compartment model; a capacitance bed that provides volume to a hydraulic pump that generates flow into an impedance bed. Any hemodynamic abnormality can be characterized by disturbances of one or more of these three variables. The surrogates for venous capacitance pressure, hydraulic pump function, and impedance are RAP, \(CO\), and systemic vascular resistance \((\text{SVR})\), respectively. Invasive monitoring is frequently not in place on initial presentation, and, given the controversies surrounding its risks and benefits,\(^5\) it is prudent to utilize readily available physical examination surrogates to define the model variables. Estimation of the RAP from the internal jugular vein approximates the pressure in the venous capacitance system, and the pulse character and temperature of the extremities approximate impedance \((\text{ie, resistance})\). Warm flushed extremities with a wide pulse pressure indicate low impedance \((\text{ie, resistance})\), whereas cool constricted extremities with a narrow thready pulse suggest high impedance \((\text{ie, resistance})\). The latter is a consequence of the catecholamine-mediated vasoconstriction that is initiated to create perfusion pressure gradients to redistribute and optimize the low-flow state. In shock patients, flow and resistance are
almost uniformly reciprocal (Qflow × resistance = pressure or CO × SVR = BP). Therefore, the initial assessment of impedance (ie, resistance) allows for the inferential derivation of hydraulic flow (ie, CO). Obviously, invasive monitoring will be needed if the physical examination findings cannot be well-characterized. Representative examples are illustrated in Figure 3.

**Pathophysiology**

**Mechanism of Cardiac Failure**

Cardiac failure from MPE results from a combination of the increased wall stress and cardiac ischemia that comprise RV function and impair left ventricular (LV) output. Research from animal models and evidence from clinical investigations clearly demonstrate that the impact of embolic material on the pulmonary vascular outflow tract precipitates an increase in RV impedance. This initiates the vicious pathophysiologic cycle depicted in Figure 4. The degree of increase in RV impedance is predominantly related to the interaction of the mechanical obstruction with the underlying cardiopulmonary status.51–53 Additional factors reported to contribute to increased RV impedance include pulmonary vasoconstriction induced by neural reflexes,54 the release of humoral factors55 from platelets (ie, serotonin and platelet activating factor), plasma (ie, thrombin and vasoactive peptides C3a, C5a), tissue (ie, histamine), and systemic arterial hypoxia.56 The acute development of this increased RV impedance constitutes a pressure afterload on the RV and has multiple effects on RV and LV function.

Given the reciprocal relationship between RV stroke volume and vascular load, RV stroke volume will diminish with increasing load.57 Initially, the compensatory maintenance of CO is achieved by a combination of catecholamine-driven tachycardia and the utilization of the Frank-Starling preload reserve (the latter being responsible for RV dilatation). This increase in RV cavity pressure and radius serves to significantly increase RV wall stress (wall stress = pressure × radius). This is the primary determinant of RV oxygen uptake, thus creating the potential for RV ischemia. With increasing RV load and wall stress, RV systolic function becomes depressed and CO begins to decrease. Interestingly, systemic BP may be adequately maintained by systemic vasoconstriction at this point.58 From the point of initial CO depression, it has been reported59 that increases in load sufficient to further decrease CO by 20% will result in a disproportionate increase in end-systolic volume compared to end-diastolic volume. Afterload mismatch has been used to describe the phenomenon of RV pressure work exceeding RV volume work in this setting.60 As a consequence of this mismatch, LV preload will decrease, given the ventricular alignment in series. LV preload is additionally impared by decreased LV distensibility as a
consequence of a leftward shift of the interventricular septum and of pericardial restraint, both of which are related to the degree of RV dilatation. It also has been suggested that MPE may impair LV function independently of preload mechanisms. In the presence of declining LV forward flow, MAP can be maintained only by catecholamine-induced vasoconstriction. A further decrease in LV flow results in systemic hypotension. RV coronary perfusion pressure (CPP) depends on the gradient between the MAP and the RV subendocardial pressure. Decreases in MAP associated with increases in RV end-diastolic pressure (RVEDP) impair the subendocardial perfusion and oxygen supply. Elevated right-sided pressures can further impair coronary perfusion and LV distensibility by increasing coronary venous pressure. Increased oxygen demands associated with elevated wall stress coupled with decreased oxygen supply have been shown to precipitate RV ischemia, which is thought to be the cause of RV failure. Clinical evidence of RV infarction as a consequence of the preceding condition has been demonstrated in patients with and without obstructive coronary disease. A reversal of PE-induced RV ischemia and RV failure can be accomplished by the infusion of vasoconstrictors to raise aortic pressure and to increase the coronary perfusion gradient.

Translation of the pathophysiology of MPE into the previously discussed three-compartment hydraulic model of the circulation is shown in Figure 5. Catecholamine-induced vasoconstriction increases the PVC to maintain a pressure gradient for VR in response to the PE-induced RAP elevation. The impairment of RV hydraulic pump function compromises LV hydraulic output, which is manifested as systemic arterial hypotension. Thus, the model variables would reveal an increased RAP, a decreased CO, and an increased SVR. The clinical correlates would be jugular venous distention, a thready pulse, and cool extremities, respectively.

Gas Exchange

Gas-exchange abnormalities in patients with PE are complex and are related to the size and character of the embolic material, the extent of the occlusion, the underlying cardiopulmonary status and the length of time since embolization. Hypoxemia has been attributed to an increase in alveolar dead space, right-to-left shunting, ventilation/perfusion (V/Q) inequality, and a low mixed venous O₂ level. The two latter mechanisms are proposed to account for the majority of observed hypoxia and hypocarbia before and after treatment. Low V/Q ratios reportedly can develop as a consequence of
the redistribution of blood flow away from the embolized area, resulting in overperfusion of the unembolized lung regions\(^7\) and atelectasis that initially develops distal to the embolic obstruction yet persists after early embolism dissolution and resultant reperfusion.\(^7\) Atelectasis may arise from a loss of surfactant and alveolar hemorrhage,\(^7\) or an “air shift” phenomenon as regional hypocarbia related to regional hypoperfusion induces bronchoconstriction,\(^8\) both of which are compounded by humoral mediators released from platelet-laden emboli.\(^1\) Postembolic pulmonary edema and flow through a patent foramen ovale that is induced by high RAP also have been implicated.\(^8\) In patients with massive PEs and circulatory failure, it has been reported that the augmentation of a low CO with medical therapy can decrease the Pa\(_{O_2}\). This was attributed to an increase in physiologic shunting because of increased flow through areas with low V/Q ratios and may explain some of the Pa\(_{O_2}\) variability in reported series.\(^8\)

**Role of Severity of Pulmonary Vascular Obstruction**

**Without Prior CPD:** It is particularly instructive to review the clinical manifestations of PE in patients without prior CPD because it allows for the examination of the pure effects of the disease and the specific compensatory responses. In this population, the clinical and physiologic manifestations of the disease are directly related to embolism size.\(^3\),\(^8\),\(^4\),\(^5\) Good correlation has been observed between the degree of angiographic obstruction and mean pulmonary artery pressure (mPAP), RAP, Pa\(_{O_2}\), and pulse.\(^3\),\(^7\),\(^8\),\(^5\) In the absence of angiographic quantification, it has been suggested that a pulmonary vascular resistance (PVR) of >500 dyne \(\cdot\) s \(\cdot\) cm\(^{-5}\) is associated with >50\% obstruction.\(^6\) Depression of the Pa\(_{O_2}\) is frequent, occurs with as little as 13\% obstruction, usually is the only clinical manifestation when the obstruction is \(\leq 25\%\), and roughly quantifies the extent of the embolus.\(^5\) Pulmonary artery (PA) hypertension (normal mPAP, 20 mm Hg) is the next most frequent finding and begins to manifest only when \(\geq 25\%\) to 30\% of the pulmonary vascular bed is obstructed.\(^5\) This represents an increase in mPAP in excess of that observed in similarly described degrees of nonembolic experimental obstruction, further implicating the previously described\(^8\) neurohumoral/hypoxia mechanisms as contributing culprits. Despite massive embolic obstruction of \(\geq 50\%\), patients without prior CPD are unable to generate an mPAP of \(\geq 40\) mm Hg, which appears to be the maximal pressure that a healthy ventricle can generate.\(^8\),\(^5\) Either a single massive embolus or the cumulative incremental effects of multiple recurrent emboli totaling \(\geq 75\%\) obstruction would necessitate an mPAP of \(\geq 40\) mm Hg and, consequently, would precipitate RV failure.\(^8\) Accordingly, mPAP values of \(\geq 40\) mm Hg represent either the baseline underlying CPD or the cumula-

**Figure 5. Hydraulic model of MPE.**
tive effects of multiple embolic events over a greater period of time, allowing for RV hypertrophy. Although correlated with the degree of anatomic obstruction, mPAP was not a reliable predictor of cardiac impairment. At high levels of mPAP (ie, 30 to 40 mm Hg), elevations or depressions in CO were observed.37,85 This suggests that the range of RV failure is narrow with individual patient variation and that an mPAP of 30 to 40 mm Hg should be considered to represent severe pulmonary hypertension in patients without prior CPD.85 The relationship between PVR and the degree of anatomic obstruction is hyperbolic and not linear. A dramatic increase in PVR occurs when obstruction exceeds 60%.89 Insofar as pressure increase in PVR occurs when obstruction exceeds obstruction is hyperbolic and not linear. A dramatic increase in PVR occurs when obstruction exceeds 60%.89 Insofar as pressure = flow × resistance, it should be recognized that mPAP can be less than expected in the presence of massive obstruction if the RV is failing and cannot generate forward flow.32

Increased RAP in the setting of PE almost always indicates severe pulmonary vascular obstruction in the absence of other CPD. RAP elevation is directly related to mPAP but occurs less frequently and is unusual until mPAP is ≥ 30 mm Hg and obstruction exceeds 35 to 40%. RAP is consistently elevated with an mPAP of ≥ 30 mm Hg, and it has been reported that a RAP of ≥ 10 mm Hg is generated by an obstruction ≥ 50%, whereas obstruction ≤ 25% is associated with a RAP of ≤ 10 mm Hg.84,85 However, it should be recognized that substantial obstruction (ie, ≥ 30%) can occur without significant elevations in RAP in this population.85 Elevations in RAP reflect the compensatory use of the Frank-Starling preload mechanism. Thus, RAP can be elevated without a decrease in CO in patients with PE, but, as a corollary, a decrease in CO without an increase in RAP should suggest an alternative non-PE diagnosis. Significant elevations in RAP indicate severe RV outflow obstruction providing a reliable index of the degree of encroachment on RV reserve. In patients without prior CPD, CO is characteristically normal or elevated despite substantial anatomic obstruction.85 A hypoxically mediated sympathetic response that augments inotropic/chronotropic responses and vasoconstriction is reported to be the responsible mechanism.90,91 The latter results in the creation of a more favorable pressure gradient for VR, resulting in an augmented Frank-Starling preload response. This is consistent with the observation that CO is initially maintained by increased stroke volume rather than increased heart rate.85 A decrease in CO is unusual without at least a 50% obstruction.85 The inadequacy of these mechanisms results in cardiac failure that is characterized by RV dilatation and by increased mPAP that is associated with an increased RAP and a predominantly chronotropic response. Insofar as BP is the product of CO and SVR (ie, BP = CO × SVR), it is likely that hypotension will ensue when systemic vasoconstriction is inadequate to generate pressure in response to decreasing flow. Thus, it appears that there exists a hierarchic series of compensatory cardiovascular responses related to the magnitude of the embolic event, with hemodynamic instability defining exhaustion and the failure of the available compensatory measures.

With Prior CPD: In contrast to patients without prior CPD, patients with prior CPD characteristically manifest a greater degree of cardiovascular impairment with a lesser degree of pulmonary vascular obstruction.92 In the Urokinase Embolic Pulmonary massive PE trial,93 90% of the patients who presented in shock had prior CPD, and 56% of the patients with prior CPD presented in shock, compared to 2% of patients without CPD. Massive obstruction of ≥ 50% is uncommonly reported in this population, which suggests that patients with prior CPD who sustain such a massive embolic event often do not survive to be studied or entered into clinical trials. In patients with prior CPD, it has been shown that the level of mPAP is disproportionate to the degree of angiographic obstruction when compared to patients without prior CPD. In a group of patients with prior CPD and a mean angiographic obstruction of only 23%, significant elevations in mPAP were reported. The increased mPAP directly correlated with pulmonary capillary wedge pressure (PCWP),92 which suggests that increased mPAP in this population is predominately related to the critical opening pressure for pulmonary flow rather than to incremental resistance in the pulmonary vasculature.94 This degree of obstruction is below the threshold to elicit increased mPAP in patients without prior CPD. In the group with prior CPD, the average mPAP was 40 mm Hg, which was the maximum seen in patients without prior CPD.92 With prior CPD, the predictive value of the PaO2 and RAP to define the extent of the vascular obstruction was lost. In contrast to patients without prior CPD, RAP was shown to be an unreliable indicator of the severity of the event, limiting its usefulness as the sign of an extensive and life-threatening vascular obstruction.92 Despite a lesser degree of obstruction, CO was uniformly below normal and independent of the magnitude of the obstruction and the level of pulmonary hypertension. Therefore, it appears that no consistent relationship exists between the degree of cardiovascular and RV functional impairment and the magnitude of the embolic obstruction in patients with prior CPD. As such, hemodynamic and RV functional status can be misleading as measurements of the effect of the embolic event and clearly illus-
trate that the estimation of the role and severity of PE in this population is predicated on the consideration of the preembolic cardiopulmonary status and the magnitude of the embolic obstruction. Determining the relative contributions of cardiopulmonary status and embolism magnitude to the postembolic hemodynamic presentation is difficult yet intuitively appealing, as such a characterization could have therapeutic and prognostic implications. The ratio of the mPAP to the percentage of angiographic obstruction has been proposed to distinguish between instances in which the PE is the primary determinant of the hemodynamic abnormality vs those instances in which the prior cardiopulmonary status dominates. In patients with prior CPD, a ratio ≥ 1.0 was consistently found, which suggests a greater pulmonary hypertensive response per unit of vascular obstruction that is consistent with less reserve in the system.

**INCIDENCE AND PRESENTATION**

It has been estimated that hemodynamically unstable MPE constitutes 10% of all PE presentations, although this percentage may be higher given the aforementioned selection bias issues. In the UPET, the Urokinase-Streptokinase Embolism Trial (USPET), and the ICOPER, 9% (14 of 160 patients), 7% (12 of 167 patients), and 4.2% (103 of 2,454 patients) of all patients, respectively, initially presented in shock. In the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), 10% (38 of 383 patients) presented in shock. In the MAPPET, which required pulmonary hypertension or right heart failure due to PE, the incidence of cardiac arrest was 18% (176 of 1,001 patients).

**Signs and Symptoms**

Given the above-reported incidence, the signs and symptoms of MPE are derived from small numbers of patients in the reported series. In the PIOPED, when patients were stratified according to their presenting syndromes, the clinical characteristics of patients with circulatory collapse were derived from five patients. The signs and symptoms of MPE in the 40 patients without CPD in both the UPET and the USPET are compiled in Table 1.

**Table 1—Signs and Symptoms of Major PE in Patients Without CPD in UPET and USPET**

<table>
<thead>
<tr>
<th>Signs and Symptoms</th>
<th>Shock (n = 21)</th>
<th>Syncope (n = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tachycardia ≥ 100 beats/min</td>
<td>86</td>
<td>38</td>
</tr>
<tr>
<td>Tachypnea ≥ 20 breaths/min</td>
<td>81</td>
<td>89</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>71</td>
<td>90</td>
</tr>
<tr>
<td>Apprehension</td>
<td>71</td>
<td>74</td>
</tr>
<tr>
<td>Accentuated P₂</td>
<td>62</td>
<td>70</td>
</tr>
<tr>
<td>Rales</td>
<td>48</td>
<td>47</td>
</tr>
<tr>
<td>Fever (temperature ≥ 37.5°C)</td>
<td>43</td>
<td>21</td>
</tr>
<tr>
<td>Pleuritic pain</td>
<td>38</td>
<td>63</td>
</tr>
<tr>
<td>Cough</td>
<td>33</td>
<td>42</td>
</tr>
<tr>
<td>DVT</td>
<td>19</td>
<td>42</td>
</tr>
<tr>
<td>Hemoptysis</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

*Table adapted from Stein et al.*
patients) developed central chest pain simulating myocardial infarction. In 45% of patients (11 of 23), there were historical signs and symptoms that were suggestive of minor PE in the week preceding the MPE presentation. In the MAPPET, 70% of patients (696 of 1,001) had an acute onset of symptoms for < 48 h, 96% of patients (958 of 1,001) were dyspneic, and 71% of patients (710 of 1,001) had a pulse rate of ≥ 100 beats/min. Unfortunately, signs and symptoms from the various hemodynamic subgroups in the MAPPET are not available. Prominent physical findings in the group investigated by Miller and Sutton included an arterial pulse that was sharp and of small volume, tachycardia, clinical RV failure with an elevated jugular venous pressure, a gallop rhythm at the left sternal edge, and an accentuated second heart sound. RV hypertrophy was never present on palpation. Physical signs were influenced by the duration of the embolism. For those patients evaluated within 24 h, sinus tachycardia and signs of RV failure (ie, elevated jugular venous pressure and gallop rhythm) were uniformly present but were less frequently observed in those presenting ≥ 24 h after the initial event. The preceding signs and symptoms were confirmed by cardiac catheterization, and their presence suggests that the time to presentation contributes an additional dimension to the findings at presentation. In the PIOPED, patients without CPD, with the following associations between signs and symptoms, and the more extreme hemodynamics were noted: third heart sound (mPAP, 39 mm Hg; RAP, 12 mm Hg); RV lift (mPAP, 28 mm Hg; RAP, 8 mm Hg); palpitations (mPAP, 27 mm Hg; RAP, 6 mm Hg); and diaphoresis (mPAP, 26 mm Hg; RAP, 8 mm Hg). In the USPET, the following were more common in PE shock patients: syncope; cyanosis; diaphoresis; pulse rate ≥ 120 beats/min; respiratory rate > 30 breaths/min; and hepatomegaly. This suggests that the presenting signs and symptoms of MPE, although similar to general PE presentations, are reflective of a more extreme and exaggerated response to the embolic phenomena. Occasionally, invasive monitoring will be in place at the onset of symptoms, which should complement the following hydraulic characterization from a physical examination: an increase in RAP; an increase in PA pressure (PAP); a decrease in cardiac index; and an increase in SVR. The validity of PCWP measurements in patients with massive PE have been questioned because the pressure can be recorded in a vascular zone that is occluded. Using the criteria of an atrial waveform and a PCWP that is lower than the PA diastolic pressure, the PCWP has been reported as being normal in patients experiencing massive PE. It has been suggested that the shift in the interventricular septum can distort the LV pressure-volume relationship, potentially producing a “normal" PCWP in the presence of the expected low LV cavitary volume. Patients with CPD can manifest similar findings but commonly have complex presentations that may be dominated by their underlying disease.

Basic Diagnostic Findings

The early generation of a differential diagnosis in hemodynamically unstable patients is usually dependent on elements derived from their medical histories and associated risk factors, physical findings, and the basic but readily available diagnostic studies (ie, ECG, chest radiograph [CXR], and arterial blood gas measurement). Definitive studies for PE are rarely available in the first hour of clinical presentation, therefore, recognizing the manifestations of MPE from the preceding is crucial to ensure that MPE is appropriately incorporated into the differential diagnosis. Utilizing the previously described hydraulic model of the circulation, physical findings reflective of MPE physiology in patients without CPD can be defined by a characteristic pattern and by the differential diagnosis shown in Figure 5. Increased RAP that is reflective of elevated right heart and venous capacitance pressures in conjunction with high arterial impedance and low cardiac flow (ie, narrow pulse pressure and cool extremities) against the background of relatively clear lungs with impaired gas exchange isolates the hemodynamic lesion to the right heart with a differential diagnosis of PE, RV infarct, pericardial tamponade, effusive-constrictive disease, and decompensated pulmonary hypertension. No risk factors that are specific for MPE have been identified, therefore, it is reasonable to assume that the well-described risk factors for PE, which are reviewed elsewhere, are applicable.

ECG

Since the initial description in 1935 by McGinn and White of the S1Q3T3 complex in seven patients with PE-induced cor pulmonale, a myriad of ECG manifestations have been reported. Several points from large series regarding ECG findings for PE, in general, warrant emphasis. First, a normal ECG is unusual and was reported in only 14% of UPET patients without CPD (massive PE, 6%; submassive PE, 23%) and 30% of PIOPED patients without CPD. Second, rhythm disturbances are uncommon. The incidence of atrial fibrillation/flutter is reported as being between 0% and 5%, and first-degree, second-degree, or third-degree heart blocks or ventricular dysrhythmias are
rare.\textsuperscript{97,109} Third, the most common ECG findings are abnormalities in the ST segment and T wave. In the UPET,\textsuperscript{109} nonspecific T changes occurred in 42\% of patients and ST-segment elevation or depression occurred in 42\% of patients. In the PIOPED,\textsuperscript{97} 49\% of patients had nonspecific ST-segment or T-wave abnormalities. In other series,\textsuperscript{111–115} an isolated T-wave inversion occurring in 46 to 68\% of patients was observed to be the most common abnormality. Fourth, the ECG abnormalities associated with PE are usually transient, with abnormalities of depolarization normalizing earlier than repolarization.\textsuperscript{97,109} The rapidity and extent of the resolution of the T-wave inversions have been shown to correlate with the therapeutic efficacy of thrombolytic agents.\textsuperscript{113,114}

The ECG manifestations of PE are thought to be related to the severity of the embolism when it is defined by lung scans or pulmonary angiograms.\textsuperscript{109,113,114,116,117} In the UPET,\textsuperscript{109} patients with ST-segment abnormalities, T-wave inversion, pseudoinfarct pattern, right axis, incomplete RBBB, and an S\textsubscript{1}Q\textsubscript{3}T\textsubscript{3} pattern had larger perfusion defects. An S\textsubscript{1}S\textsubscript{2}S\textsubscript{3} pattern, and all of the preceding patterns except the S\textsubscript{1}Q\textsubscript{3}T\textsubscript{3} pattern, were associated with a higher FAP and RVEDP. RV stroke work and PVR were not related to ECG abnormalities.\textsuperscript{109} The ECG correlate of acute cor pulmonale (ie, right axis deviation, complete or incomplete RBBB, S\textsubscript{1}Q\textsubscript{3}T\textsubscript{3}, and P pulmonale) occurred in 32\% of patients with massive PEs in the UPET.\textsuperscript{109} In the series by Miller and Sutton\textsuperscript{32} of 23 patients without CPD and with massive PEs and shock, 78\% showed abnormalities of conduction or repolarization of the RV. RBBB was present in 22\% of patients, S\textsubscript{1}Q\textsubscript{3}T\textsubscript{3} pattern and T-wave inversion in V\textsubscript{1} through V\textsubscript{4} was present in 27\% of patients, an rSR pattern in V\textsubscript{1} was present in 17\% of patients, an S\textsubscript{1}Q\textsubscript{3}T\textsubscript{3} pattern and an inverted T wave in the avF was present in 17\% of patients, and a normal ECG was present in 17\% of patients. In two studies, the pattern of anterior T-wave inversions in the precordial leads has been shown to represent the ECG finding that best correlates with the severity of the PE.\textsuperscript{113,114} This occurred in 85\% of patients with massive PEs vs 19\% of those with nonmassive PEs, and, when present, 90\% of patients had an obstruction score of \( \geq 50\% \) and 81\% had an mPAP of \( \geq 30 \) mm Hg. The early appearance of the pattern is an even stronger predictor of severity. When the pattern was present on day 1, the obstruction score was 69\% compared to 52\% when it developed after day 1. Pattern reversibility correlated with physiologic resolution, particularly in patients receiving thrombolytic therapy. In this group, the early normalization of the T-wave inversion pattern was reflective of significant physiologic improvement, which was evidenced by a postlysis mean obstruction score of \(< 20\%\) and a mean mPAP of \(< 20 \) mm Hg, with average changes of 57\% and 18 mm Hg, respectively.\textsuperscript{114}

The physiologic basis for the ECG changes associated with PE remain undefined. In a series of experimental and clinical observations in 1938, Love et al\textsuperscript{118} concluded that RV dilatation was responsible as they observed ECG changes that were similar to those of PE with mechanical obstruction of the PA and noted that visible RV dilatation uniformly preceded the ECG changes. Several observations\textsuperscript{114,119} argue against this phenomenon as the sole cause. The clinically observed lag time between the onset of RV dilatation/pulmonary hypertension and the ECG changes can range from hours to days, there can be a persistence of the ECG changes for days after angiographic and hemodynamic resolution, and echocardiographically documented, PE-induced RV dilatation does not uniformly produce ECG changes.\textsuperscript{114,119}

In view of early reports of PE-induced myocardial infarction in patients with massive PEs and normal coronary arteries,\textsuperscript{64,120–122} it is conceptually appealing to attribute the ECG findings to myocardial ischemia\textsuperscript{121} and/or to RV wall stress.\textsuperscript{123} However, two reports\textsuperscript{113,124} utilizing early myocardial scintigraphy with MIBI and CKP enzyme assessment in patients with anterior T-wave changes have failed to demonstrate perfusion defects or enzyme leaks that are suggestive of ischemia.

CXR

The CXR cannot be used to include or exclude the diagnosis of MPE. Albeit nonspecific, the CXR contributes to the diagnostic assessment of MPE by excluding diseases that mimic PE, by defining abnormalities that warrant further evaluation, and by providing a crude estimate of severity.\textsuperscript{125} A normal CXR in patients with proven PE is unusual and occurred in only 16\% and 34\%, respectively, of patients in the PIOPED\textsuperscript{97} and UPET\textsuperscript{126} who were free of CPD. An association between PE severity and radiographic findings is supported by examining the relationships among the PAP, the alveolar-arterial oxygen pressure difference (P[A-a]O\textsubscript{2}), and the CXR findings in PIOPED patients. The lowest values for both were observed in patients with a normal CXR, whereas higher values were related to parenchymal and vascular findings.\textsuperscript{125} Vascular findings appear to be more indicative of PE severity. In the UPET,\textsuperscript{126} a normal CXR and parenchymal signs occurred with comparable frequency among patients with massive PEs (ie, affecting two or more lobar arteries) and submassive PEs. However, vascular signs, particularly focal oligemia and/or distention of the proximal portion of the PA were more common in massive

CHEST / 121 / 3 / MARCH, 2002  887

Downloaded from www.chestjournal.org at Mount Sinai School of Medicine on February 6, 2007.
than submassive PEs (43% vs 28%, respectively). Similarly, in large case series concerning patients with obstruction of ≥ 50%, McDonald et al reported oligemia in 44% of patients, and Miller and Sutton uniformly found oligemia in patients without CPD and shock. Kerr et al observed oligemia in all patients, with the angiographically defined area evident in 79% of CXRs and hyperemia secondary to blood flow redistribution defined in 40% of CXRs. Thus, whether alone or in conjunction with other CXR abnormalities, focal oligemia should foster a heightened sense of awareness for PE in the patient with undifferentiated shock.

Arterial Blood Gas Analysis

Despite the impressive list of physiologic abnormalities that are responsible for hypoxemia in patients with PE, several caveats from large series should be recognized regarding the use of blood gas analysis in the diagnostic assessment of PE. First, hypoxemia is not uniform, as a PaO2 of ≥ 80 mm Hg was seen in 12% of the UPET patients and in 19% of the PIOPED patients. Second, a normal P(A-a)O2 does not exclude PE and occurred in 14% of the PIOPED patients. Among patients who had PaO2 values (≥ 80 mm Hg) and Paco2 values (≥ 35 mm Hg) that were not low and a normal P(A-a)O2, 38% of patients without CPD and 14% of patients with CPD had angiographically proven PE in PIOPED. Given the reported relationship between PE severity and PaO2 or P(A-a)O2, the preceding values most likely reflect the presence of minor PEs. McIntyre and Sasahara reported a linear relationship between PE severity and PaO2 or P(A-a)O2, and the mPAP and cardiac index) and PaO2 levels in patients without CPD, but no correlation was found in patients with CPD. In PIOPED patients with and without CPD, a close correlation was observed between the P(A-a)O2 and the mPAP and the number of mismatched perfusion defects. For example, in patients with a P(A-a)O2 of ≥ 20 mm Hg, the mPAP was ≤ 20 mm Hg and the number of mismatched vascular perfusion defects was three or less. Hypocarbia and the accompanying respiratory alkalosis are common in patients with PEs, as even patients with baseline CO2 retentive lung disease will reduce their Paco2 level after experiencing a PE. In patients with MPE, both respiratory and metabolic acidosis may be present, the former as a consequence of increased physiologic dead space ventilation (Vd/Vt) and respiratory muscle use, and the latter when related to tissue hypoperfusion with shock.

Contemporarily, the use of Vd/Vt determinations and the d-dimer assay is not standard or universally available, as their role is being defined by the evolution of the literature. An increase in alveolar Vd/Vt is an inevitable consequence of PE, which can be quantified by measuring the volume and partial pressure of CO2 with bag collection or end-tidal CO2 by capnography. Studies that compared Vd/Vt measurements to PE defined by V/Q scanning and/or angiograms showed excellent sensitivity (≥ 90%) and specificity (≥ 85%). In a study of critically ill surgery patients that included patients with ARDS who were receiving mechanical ventilation, Vd/Vt measurements had a sensitivity of 100% and a specificity of 89%. It has been reported that Vd/Vt measurements correlate with the degree of vascular obstruction and its resolution with thrombolytic therapy. Elevated levels of d-dimer are found in patients with deep venous thrombosis (DVT) and/or PE and in patients with many other clinical conditions in which fibrin cross-links are cleaved by plasmin, which accounts for the low reported specificity. The high sensitivity and corresponding negative predictive values potentially make it an ideal test to exclude the presence of PE. The standard enzyme-linked immunosorbent assay provides an accurate quantitative measurement but it is expensive and labor intensive. The enzyme-linked immunosorbent assay method utilizes batch analysis, not single-patient analysis that requires 2 to 4 h to perform, which essentially precludes its use in the golden hour of MPE. The semi-quantitative latex assay is faster and less expensive but has a low and unacceptable sensitivity. The new generation of rapid d-dimer assays can provide accurate results within minutes and may soon be incorporated into the standard diagnostic evaluation.

Utilizing the basic and readily available data, a differential diagnosis is constructed and a clinical suspicion for PE is cultivated. The latter is important because clinical suspicion, when combined with the findings of V/Q scanning, has been shown to establish the diagnosis or to define the need for further, more definitive diagnostic testing.

Diagnostic-Therapeutic Approach

Shock as a Discriminator

The most consistent operational definition of shock in the PE literature is the presence of hemodynamic instability. With a literature span of 30 years and data predominately derived from case series and subsets of patients from various trials, there is no standard definition. At a minimum, this pragmatic definition requires the presence of hypotension (ie, systolic BP ≤ 90 mm Hg) and/or the use of vaso-
pressor therapy. The presence of shock in patients with acute PE, either as a consequence of a massive PE in patients without CPD or as a consequence of a submassive PE in patients with CPD, represents a failure of the available compensatory mechanisms to sustain BP and/or tissue perfusion and is associated with a significant increase in mortality. Shock provides an early, readily available, and reliable discriminator between survivors and nonsurvivors. Tables 2 and 3 illustrate the relationships among shock, embolism size, and outcome that have been reported in large series. Uniformly, the presence of shock is associated with a threefold to sevenfold increase in mortality.\textsuperscript{35,96} and in 64% of patients in the USPET.\textsuperscript{96} The vast majority of patients with anatomically massive PEs do not present in shock;\textsuperscript{35,39,46,155–157} Menke et al\textsuperscript{158} reported that only 2 of 66 patients without CPD and with massive PEs required vasopressor therapy and that CO was normal in 97% of patients. It is important to recognize that hemodynamically stable patients who are not in shock but who have experienced massive or submassive PE have similar mortality rates.\textsuperscript{35,39} A massive PE, unless accompanied by shock and hemodynamic instability, does not appear to be associated with an increased mortality rate.\textsuperscript{35,39,46,100,155–158} Several large series\textsuperscript{45,46,158} have reported a 0% mortality rate in patients with massive PEs who were not in shock, and others\textsuperscript{35,39,44,47,100,155–157,159} have reported a 3 to 8% range.

The preceding observations are best exemplified in the series by Alpert et al\textsuperscript{39} and in the UPET\textsuperscript{35} in which the mortality rates for patients in shock compared to those not in shock were reported (Alpert et al, 25% vs 5%, respectively; UPET, 36% vs 5%, respectively). In the series by Alpert et al,\textsuperscript{39} the mortality rate for hemodynamically stable non-shock patients with massive PEs was 6.5% compared to 8.8% for all patients.\textsuperscript{30} In the UPET,\textsuperscript{35} the mortality rate for these patients was 5.1% compared to 8.1% for the entire group. Impressively, the mortality rate for patients experiencing submassive PEs (9.8%) was slightly higher than that for those experiencing massive PEs (6.7%), as all of the patients in shock died.\textsuperscript{35} The highest mortality rate is reported in hemodynamically unstable shock patients experiencing massive PEs.\textsuperscript{35,39} Utilizing shock as an algorithmic discriminator, a diagnostic-therapeutic approach to the patient with suspected MPE is presented in Figure 6. In the nonshock patient, death within the first hour is unlikely, and the tempo of the evaluation is less urgent than that for the patient in shock. The patient should receive heparin therapy and can be transported for diagnostic assessment. Current diagnostic approaches include V/Q scanning, pulmonary angiogram, helical CT scanning, MRI, and compression ultrasound, either alone or combined in an algorithmic sequence.\textsuperscript{160–168} When perfusion defects are \( \geq 30\% \) or when anatomically massive PEs are detected, echocardiographic assessment has been advocated to identify a subpopulation with RV dysfunction. This group is reported to have a higher mortality rate with a greater risk of recurrence and may benefit from thrombolysis, although this treatment is controversial.\textsuperscript{41} In contrast, the shock patient is much more likely to die within the first hour, and the tempo of the evaluation must be rapid. Ideally, the diagnostic evaluation should begin in the area where the patient can be optimally resuscitated and stabilized. Duplex venous ultrasound is appealing because it is readily available, has excellent sensitivity and specificity for DVT in symptomatic patients, and a positive finding can exploit the identical treatment for DVT and PE.\textsuperscript{163} Although venogram-detected DVT has been reported in 70 to 90% of PE patients,\textsuperscript{164–166} the documentation of DVT by ultrasound occurs in \(< 50\% \) of PE patients.\textsuperscript{164,167,168} The absence of DVT by ultrasound does not preclude PE, and the presence of DVT does not confirm PE as the primary culprit, as DVT may be incidental to another life-threatening process. Therefore, ultrasound is of limited utility in the initial evaluation of

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline
\textbf{Study} & \textbf{Shock Patients} & \textbf{Nonshock Patients} & \textbf{Patients With Massive PEs in Shock} & \textbf{Patients With Nonmassive PEs in Shock} & \textbf{Patients With Massive PEs Not in Shock} & \textbf{Patients With Nonmassive PEs Not in Shock} \\
\hline
UPET\textsuperscript{35} (n = 160)† & 9/36 & 91/6 & 12/18 & 4/100 & 88/5 & 96/6 \\
\hline
Alpert et al\textsuperscript{39} (n = 136)† & 21/25 & 79/5 & 38/32 & 11/11 & 62/7 & 90/4 \\
\hline
\end{tabular}
\caption{Relationships Among Shock, Embolism Size, and Outcome*}
\label{table2}
\end{table}

*Values given as patients, %/mortality, %.
†Treatment with heparin or urokinase.
‡Treatment with heparin or ligation.
shock patients but may later assist in the decision to place an inferior vena cava (IVC) filter or to define independently an indication to anticoagulate.

**Echocardiography**

Echocardiography (ECHO) is enormously useful in this setting because it is readily available and repeatable, is useful in the recognition and differentiation of PE, and is capable of assessing the severity of the PE and the patient’s response to therapy.169–171 In the MAPPET,13 ECHO was the most frequent diagnostic procedure that was performed in 74% of patients. Although predominantly employed to characterize the presence and the extent of RV pressure overload, transthoracic ECHO (TTE) or transesophageal ECHO (TEE) may detect emboli in transit or may provide alternative diagnoses, such as aortic dissection, pericardial disease, hypovolemia, myocardial dysfunction/infarction, and valvular insufficiency.172,173 The latter two were the most common alternative diagnoses in a study in which definitive echocardiographic findings excluded PE in 42% of patients who were evaluated for suspected PE.174 ECHO also may be helpful in identifying PE patients with a patent foramen ovale, which is associated with increased mortality, ischemic stroke, and a complicated course.175 Echocardiographic findings of PE-induced RV pressure overload include the following: RV dilatation/hypokinesis with an increased RV/LV diameter ratio; paradoxical septal motion; PA dilatation; and tricuspid regurgitation (TR).105,169–171,173 In patients without CPD, the presence and extent of the above findings correlate with the degree of pulmonary outflow obstruction.105,172,173,176–178 RV dilatation is the most common finding and is reported to occur in 50 to 100% of PE cases.172–174,176–180 It appears that an obstruction of ≥30% is required to produce RV dilatation,176,181,182 which approximates the previously reported85,129 degree of

### Table 3—Anatomically Massive PE Relationship Between Shock and Outcome

<table>
<thead>
<tr>
<th>Study/Year</th>
<th>Treatment</th>
<th>Shock, %</th>
<th>Mortality, %</th>
<th>Nonshock, %</th>
<th>Mortality, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miller et al190/1977</td>
<td>Heparin, lysis, embolectomy</td>
<td>60</td>
<td>22</td>
<td>40</td>
<td>7</td>
</tr>
<tr>
<td>Marini et al190/1988</td>
<td>Urokinase/heparin</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Verstraete et al190/1988</td>
<td>rt-PA</td>
<td>21</td>
<td>14</td>
<td>79</td>
<td>4</td>
</tr>
<tr>
<td>Tilsner190/1991</td>
<td>Urokinase</td>
<td>11</td>
<td>40</td>
<td>89</td>
<td>2</td>
</tr>
<tr>
<td>Diehl et al190/1992</td>
<td>rt-PA</td>
<td>33</td>
<td>22</td>
<td>67</td>
<td>3</td>
</tr>
<tr>
<td>Sors et al190/1994</td>
<td>rt-PA</td>
<td>17</td>
<td>0</td>
<td>83</td>
<td>0</td>
</tr>
<tr>
<td>Meneveau et al190/1998</td>
<td>rt-PA streptokinase</td>
<td>3</td>
<td>0</td>
<td>97</td>
<td>0</td>
</tr>
</tbody>
</table>

### Major Pulmonary Embolism Diagnostic/Therapeutic Approach

![Diagram of Diagnostic-therapeutic approach to MPE](image)

**Figure 6.** Diagnostic-therapeutic approach to MPE. US = ultrasound.
obstruction that is necessary to produce increased PAP. The reported variability and overlap in the percentage of the obstruction-dilatation relationship has led to speculation that the RV pressure response to obstruction may be more important for determining RV dilatation than the absolute degree of obstruction.\textsuperscript{183} Minor PE, which is defined as an obstruction of \(\leq 20\%\) or an mPAP of \(< 20\) mm Hg, characteristically does not produce echocardiographic findings of RV pressure overload or RV dilatation.\textsuperscript{179,182} A normal echocardiogram without signs of RV pressure overload effectively eliminates PE as the cause of a shock state.\textsuperscript{170} Resuscitation, stabilization, and pursuit of an alternative diagnosis should be undertaken.

The presence of RV dilatation is not specific for PE. However, in the appropriate clinical context, patients without CPD in extremis may be considered as candidates for lysis or embolectomy without further confirmatory studies, although this treatment is controversial.\textsuperscript{172,184–187} In patients with preexisting LV pathology, ECHO has not been shown to establish the severity of a superimposed event.\textsuperscript{188} In patients with underlying CPD, RV dilatation may be representative of a spectrum of diseases ranging from RV infarct with cardiomyopathy to cor pulmonale with pulmonary hypertension. Several echocardiographic findings have been reported to be useful in differentiating PE from any of the above conditions. Patients with cor pulmonale or recurrent PE characteristically have a hypertrophied RV with a thickness of \(> 5.0\) to \(7.0\) mm,\textsuperscript{171,179} preservation of the normal inspiratory collapse of the IVC,\textsuperscript{171,176,179} and a minimal septal shift,\textsuperscript{176,179} whereas acute RV failure secondary to RV infarct or acute PE should not be accompanied by RV hypertrophy and is accompanied by a minimal collapse of the IVC with inspiration.\textsuperscript{171,172,176,179} A septal shift is more characteristic of acute PE.\textsuperscript{105,176,177,179} The maximal velocity of the TR jet is directly proportional to the peak systolic pressure gradient between the RV and RA (\(\Delta P = 4V^2\)) and can reliably be used to estimate PAP.\textsuperscript{189} The hypertrophied RV in patients with cor pulmonale or recurrent PE can generate a substantial PAP, occasionallyapproaching systemic pressures, and is associated with a TR jet of \(\geq 3.5\) to \(3.7\) m/s.\textsuperscript{176,177,179,190} RV infarct, cardiomyopathy, and dysplasia have impaired pressure-generating ability and a TR jet of \(\leq 2.5\) to \(2.8\) m/s.\textsuperscript{169,171,176,179} Acute PE appears to be intermediate with a TR jet velocity of \(> 2.5\) to \(2.8\) m/s but \(< 3.5\) to \(3.7\) m/s,\textsuperscript{169,171,172,176,177,179,191} which is consistent with the previous observations that a healthy ventricle cannot generate an mPAP of \(\geq 40\) mm Hg.\textsuperscript{85} Reported echocardiographic findings that were specific for PE include a disturbed systolic flow velocity pattern of RV ejection (sensitivity 48%, specificity 98%).\textsuperscript{192} and a distinct regional pattern of RV dysfunction with akinesia of the mid-free wall but normal motion at the apex (sensitivity, 77%; specificity, 94%).\textsuperscript{193} The latter was attributed to a tethering of the RV apex to a contracting hyperdynamic LV, the development of a more spherical shape to equalize wall stress, or localized ischemia.\textsuperscript{193}

Unless the occasional clot in transit is directly visualized, TTE provides only indirect evidence of PE. When associated with RV dilatation, the PE is almost uniformly bilateral\textsuperscript{194} and, in 50 to 90% of cases, is central or proximal, and can be reliably imaged by TEE.\textsuperscript{194–197} In several large series, patients with suspected PE and documented RV dilatation by initial TTE immediately underwent TEE. Compared to confirmatory reference standards, TEE had a sensitivity range of 80 to 96.7% and a specificity range of 84 to 100%.\textsuperscript{194–197} Comparable sensitivity to spiral CT scanning has been attributed to the ability of TEE to visualize the proximal extending, mobile parts of more distally impacted thrombi.\textsuperscript{194} For thrombi beyond the proximal pulmonary arteries, the sensitivity of TEE is reported to be lower (58%).\textsuperscript{195,197} This most likely relates to difficulty visualizing the lobar arteries and the left middle/distal PA given its relationship to the left mainstem bronchus.\textsuperscript{196} It has been suggested that utilizing a single-plane probe with rotation enables the visualization of the distal left PA and its lobar branches, which may account for the more balanced prevalence in some studies.\textsuperscript{194,198} Incorporating TEE into the diagnostic algorithm for MPE is appealing because TEE is safe and can be performed at the bedside in critically ill patients\textsuperscript{196,197,199,200} immediately after TTE in patients with RV pressure overload by the same operator with a reasonable likelihood that a definitive diagnosis will be obtained.

Confirmatory Studies

When ECHO cannot be performed or when it documents RV pressure overload but no direct evidence of thrombus, confirmatory studies are necessary. Given the unstable nature of the suspected MPE, choosing the most expeditious approach to achieve a definitive diagnosis is essential. The choice of a confirmatory study may be dictated by hospital culture, expertise, experience, and availability. Traditionally, the V/Q scan has been considered to be the first-line study, but, unfortunately, it is diagnostic only in a minority of cases. The majority of patients with angiographically documented PE (59%) do not have a high-probability scan.\textsuperscript{154} Overall, scan interpretations of normal (15%) or high probability (13%) are rare, as the majority of scans are nondiagnostic...
intermediate (39%) and low probability (34%), particularly in patients with underlying CPD.\textsuperscript{154} In patients with COPD, normal scans (5%) and high-probability scans (5%) are even less common, and nondiagnostic intermediate scans (60%) predominate.\textsuperscript{203} However, it should be recognized that the positive predictive value of high-probability, intermediate-probability, low-probability, or normal scans is preserved and does not differ between patients with or without CPD or COPD.\textsuperscript{202,203} Stratification according to the presence or absence of CPD has been shown to enhance the predictive value of PE by applying different criteria to both groups.\textsuperscript{204} In critically ill patients, the sensitivity, specificity, and positive predictive values of high-probability scans are similar to those of non-critically ill patients and are enhanced by concordant clinical assessments.\textsuperscript{205}

Performing ventilation scans in critically ill patients can be difficult.\textsuperscript{206} Isolated high-probability perfusion scans retain the same sensitivities, specificities, and predictive values even in patients receiving mechanical ventilation.\textsuperscript{205,207} Combing clinical probability with scan probability enhances the predictive value. Combinations of “high-high” or “low-low” are considered to be definitive for the diagnosis or exclusion, respectively, of PE but occur in only a minority of patients.\textsuperscript{154,208} Therefore, with the traditional V/Q scan approach, the majority of patients subsequently will require angiography as the definitive confirmatory study.\textsuperscript{209} Angiography is recognized as the “gold standard” confirmatory test but is invasive and expensive, and requires a skilled and experienced staff to perform it. Angiography is not uniformly available\textsuperscript{210} and is associated with multiple complications,\textsuperscript{209,211} particularly in critically ill patients\textsuperscript{209} and patients with pulmonary hypertension.\textsuperscript{212} In the MAPPET\textsuperscript{13} series of patients with PE related RV dysfunction and hypotension, angiography was performed in only 14% of patients. The established mandatory requirement for angiography prior to aggressive intervention with lysis or embolectomy has been questioned.\textsuperscript{154} An embolectomy series\textsuperscript{213} reported that only 30% of patients had undergone angiography prior to surgery. In patients for whom thrombolysis is a consideration, a noninvasive diagnostic approach has been advocated because of the bleeding associated with angiography.\textsuperscript{214} Thus, given the potential for a delay in diagnosis and associated complications, alternative approaches have been suggested.\textsuperscript{215}

Spiral or helical CT scanning is appealing because it is readily available, is noninvasive, and, similar to TTE and TEE, it can detect RV dilatation\textsuperscript{216} and can define an alternative diagnosis.\textsuperscript{217,218} Although no study has tested the sensitivity of spiral CT scanning in patients with suspected PEs and shock, it is highly likely that a filling defect will be demonstrated in this population. When the findings of a spiral CT scan are compared to those of an angiogram for PE in the central arteries (main artery through segmental branches), a pooled analysis of large series reported excellent sensitivity (94%), specificity (94%), and positive predictive value (93%).\textsuperscript{219–224} In cases of acute PE that were considered to be “clinically important” or associated with RV pressure overload, sensitivities and specificities approaching 100% have been reported.\textsuperscript{194,219,222} The overall sensitivity for PE with spiral CT scanning is thought to be approximately 85%,\textsuperscript{225,226} The CT scan sensitivity is somewhat lower in patients who have undergone nondiagnostic V/Q scans\textsuperscript{195,211,227} but has been useful in confirming the diagnosis in that population.\textsuperscript{221,227–229} The low sensitivity (ie, 50 to 60%) in some series\textsuperscript{230,231} has been attributed to the inconsistent ability of spiral CT to detect vessels with subsegmental PE.\textsuperscript{232} The frequency of subsegmental PE is reported to be 6%, and interobserver angiographic agreement on the presence of subsegmental PE is only 66%.\textsuperscript{233} The clinical significance of subsegmental PE is uncertain\textsuperscript{234} and, therefore, unlikely to precipitate shock. Optimal visualization with spiral CT scanning is achieved by dye injection through a proximal or central vein and by breath-holding.\textsuperscript{234} The latter is potentially problematic in the critically ill patient receiving mechanical ventilation and may require a reduction in tidal volume or a brief apneic period in the sedated and/or paralyzed patient. Similar to spiral CT scanning, MRI accurately visualizes the central vessels, provides alternative diagnoses, and reportedly has comparable sensitivity and specificity.\textsuperscript{235–237} The advantages of MRI include eliminating the nephrotoxic contrast load and the potential to undertake MR venography at the same session.\textsuperscript{237,238} However, the contraindications to MRI (ie, patient isolation and examination duration) potentially limit its utility in unstable patients. Independent of which confirmatory strategy is employed, the documented presence of PE in the hemodynamically unstable patient defines an indication for aggressive intervention either with thrombolysis or, when thrombolysis is contradicted, surgical or catheter embolectomy.

**Resuscitation and Stabilization**

Throughout the evaluation period, patients with suspected MPE often require aggressive resuscitation and ongoing stabilization. Marginal native hemodynamic stability is maintained by an intense catecholamine surge. The PE-induced increase in RAP necessitates venoconstriction, which increases PVC to maintain the pressure gradient for VR
(VR = PVC − RAP) [Fig 3]. Similarly, with hypoten-
sion related to PE-induced RV dysfunction and
increased RVEDP, systemic arterial constriction is
necessary to maintain RV CPP (RV CPP = MAP −
RVEDP) [Fig 5]. With escalating oxygen require-
ments or refractory hypoxia, patients with suspected
MPE frequently require intubation and mechanical
ventilation. Intubation can precipitate cardiovascular
collapse for several reasons. First, sedative hypnotics
used for intubation can blunt the catecholamine
surge on which the patient is dependent for vaso-
constriction as well as independently produce vaso-
dilation, both of which impair the above gradients.
Second, overzealous initial lung inflation can further
decrease VR. Third, the initiation of mechanical
ventilation can increase PVR, which can further
decompensate the RV. Accordingly, intubation
should be undertaken judiciously, weighing the rel-
ative benefits and risks of a conscious-awake tech-
nique with topical and/or local anesthesia, a rapid-
sequence approach with neuromuscular paralysis or
fiberoptic intubation. Etomidate is an ideal sedative
because it preserves hemodynamic status. Insofar as
atelectasis is the most common CXR finding, posi-
tive-pressure ventilation has been shown to improve
oxygenation in patients with PE.73,239 Jet ventilation
has been reported to have advantages over conven-
tional ventilation in patients with PE,240 and placing
the embolized lung in a dependent position has been
shown to improve oxygenation.241

Traditionally, volume expansion with 1 to 2 L
crystalloid is the initial treatment for hypotension in
patients with undifferentiated shock. In patients with
anatomically massive PEs and depressed COs who
were normotensive and without pressors, Mercat et
al242 reported increases in CO with a 500-mL dex-
tran fluid challenge. The increase in CO was univer-
sally proportional to the baseline right ventricular
end-diastolic volume index. However, in hypotensive
patients with severe RV dysfunction that is associ-
ated with high RV pressures and volumes causing
increased wall stress and/or RV ischemia and a septal
shift impairing LV compliance and/or filling, excess
fluid administration may compound these problems
and precipitate further RV deterioration.243,244
Therefore, when measured pressures are high or
when there is documented severe RV dysfunction,
fluids should be used with caution and early consid-
eration should be given to vasopressor therapy.
Patients with MPE frequently require vasoactive
support, but, unfortunately, there are limited human
data in this area. When extrapolated from animal
models, it appears that norepinephrine (NE) should
be the preferred vasopressor for MPE patients in
shock. As early as 1956, it was recognized that the
survival of a patient with MPE was dependent on the
maintenance of aortic pressures to provide adequate
coronary flow to the stressed RV.245 NE appears to
improve RV function through an α-mediated vaso-
constrictive effect on the arterial and venous
systems. The former generates a higher MAP,
which enhances RV CPP (RV CPP = MAP −
RVEDP)243,246,247 and abolishes RV ischemia,66
wheras constriction in the PVC enhances the gra-
dient for VR (VR = PVC − RAP). Additionally, NE
possesses β1 (inotropic) properties that have been
shown to provide complementary enhancement of
RV function.248,249 In patients with massive PEs and
circulatory failure, dobutamine increases CO and
overall oxygen transport but may alter V/Q relation-
ships and decrease PaO₂.246,247 Dobutamine can
cause peripheral vasodilatation through a β2 effect,
which supports the recommendation that dobut-
amine only be considered in cases of moderate
hypotension with appropriate monitoring while NE
should be utilized for patients in severe shock.70,252
Unloading the RV with pulmonary vasodilators may
be useful in patients with incipient or overt RV
failure as an adjunct to thrombolysis, in patients with
contraindications to thrombolysis or who are await-
ing embolectomy. Inhaled prostacyclin and nitric
oxide have been reported253,254 to increase CO, decrease pulmonary pressures, and improve gas ex-
change in cases of severe PE.

Heparin

When PE is first suspected, patients should re-
ceive heparin at therapeutic doses until PE is ex-
cluded, provided that no contraindications to antico-
agulation are present.255 Large doses of heparin
given as a bolus can precipitate hypotension, which is
thought to be related to histamine release as the
hemodynamic response can be blocked by histamine
1 and 2 receptor blockers.256,257 The efficacy of
heparin is attributed to an impairment of clot prop-
gagation and the prevention of recurrent PE.258 The
risk of recurrent venous thromboembolism is highest
in the early stages,259,260 and, because recurrent PE
is reported to be the most common cause of death in
hemodynamically stable patients,3,41 it is crucial to
rapidly achieve a therapeutic level of anticoagulation.
An inability to establish an early therapeutic level for
the activated partial thromboplastin time (aPTT) is
associated with a higher rate of recurrence261,262 and
improves the efficacy of anticoagulation therapy with
warfarin.263 A weight-based heparin nomogram has
been shown264 to achieve a therapeutic aPTT more
rapidly and to more effectively prevent the recur-
rence of venous thromboembolism. Although it has
been demonstrated that a course of heparin therapy
of 4 to 5 days, with warfarin initiated on day 1, is as
effective as the traditional course of heparin therapy of 9 to 10 days,265,266 this has not been studied in patients with MPE. For this population, it is recommended that heparin therapy be given for 7 to 10 days and that the initiation of warfarin therapy be delayed until the aPTT is at a therapeutic level for 3 days.267 Patients with massive PEs reportedly have higher heparin dose requirements, and substantial amounts of heparin may be needed to ensure that therapeutic anticoagulation is rapidly achieved and sustained.268 When large doses of heparin are required (ie, ≥ 40,000 U/d), the optimal heparin dose can be determined by antifactor Xa heparin levels.269

Although low-molecular-weight heparin has been shown to be safe and effective in treating patients experiencing submassive PEs with proximal DVT,10,11 its use in patients experiencing massive PEs or MPEs remains unstudied.270 It has been proposed that undergoing anticoagulation therapy with heparin will prevent the accretion of new fibrin on the thrombus, thereby facilitating lysis by thrombolytic agents and reducing the risk of re-extension after thrombolysis.271 The greater the angiographic and scintigraphic resolution observed with urokinase (UK) therapy compared to heparin therapy on day 1 in the UPET has been ascribed to a synergism between the UK and the heparin administered during the diagnostic workup prior to randomization.45

Thrombolytic Therapy

Thrombolytic therapy in patients experiencing PEs has been extensively reviewed and will be discussed only briefly.272,273 Although no definitive mortality data exist, thrombolytic therapy is uniformly acknowledged as the treatment of choice in hemodynamically unstable patients with PE.272–274 This should be interpreted similarly for patients without CPD and massive PEs or in patients with submassive PEs and CPD who are manifesting shock or cardiovascular collapse.267

In the PIOPED, thrombolytic therapy was considered to be the standard of care for patients with “shock or major disability.” The investigators considered it “unethical” to treat this group with heparin alone.46 Several points regarding thrombolytic therapy and MPE should be stressed. First, when assessed by angiography, perfusion scans, hemodynamic measurements, or ECHO, thrombolytic therapy has been shown to produce more rapid (ie, 2 to 24 h) clot lysis when compared to heparin therapy in all trials16,35,41,47,159,275 except two,45,48 No trial has reported any difference in the degree of embolic resolution after days 5 to 7. Given the hyperbolic relationship between PVR and vascular obstruction, slight decreases in obstruction (to ≤ 60%), as would be expected with thrombolysis, can significantly reduce PVR and alleviate RV stress.89 However appealing the rapid resolution of embolic obstruction may be, only one trial69 has demonstrated a mortality outcome benefit. This small trial of only eight patients should be viewed with caution. All four patients randomized to thrombolytics were treated within 4 h of presentation, whereas those patients randomized to heparin therapy had previously failed to respond to it and had experienced recurrent PEs with severe respiratory failure. Second, there does not appear to be any difference in the effectiveness of thrombolytic agents, provided that they are given in equivalent doses over the same time frame.158,276 Third, bolus therapy with recombinant tissue plasminogen activator (rt-PA) [0.6 mg/kg/15 min] is equivalent to the traditional 100 mg/2 h.36,277 Fourth, IV rt-PA appears to be equivalent to intrapulmonary rt-PA.156 Fifth, bleeding complications from thrombolytic therapy can be substantial. From pooled analysis, the overall incidence of major hemorrhage associated with PE thrombolysis is reportedly 12% and appears to be similar among thrombolytic agents.273 Fatal hemorrhaging is thought to occur in 1 to 2% of patients.278 The reported incidence of intracranial hemorrhaging ranges from 1.2 to 2.1%,272,273,279 and is fatal in at least 50% of cases.273

Embolectomy

For those patients with contraindications to thrombolytic therapy, “unyielding hypotension” despite maximal medical treatment for ≥ 1 h, or ongoing/intermittent cardiac arrest, treatment with surgical embolectomy should be considered.280 Catheter embolectomy or fragmentation is an option for patients who are not in cardiac arrest.281 Availability and expertise are limited, and in the modern era of treatment with medical embolectomy using thrombolytic therapy, surgical embolectomy is rarely performed.282 In MAPPET, only 1% of 594 patients with shock or cardiac arrest underwent the procedure.13 For patients in shock or in extremis, diagnostic confirmatory studies can delay definitive treatment and contribute to mortality.283 Several large series282–284 have reported that angiograms were performed in only 14 to 67% of patients undergoing embolectomy. Therefore, the operative decision may be based on clinical findings.284 In a compilation series, cardiopulmonary bypass appears to be the preferred operative technique and is associated with improved survival compared to venous inflow occlusion normothermic circulatory arrest (59% vs 45%).285 Proponents of the latter technique stress its greater availability, rapidity, and simplicity with comparable outcomes in selected centers.286 Partial car-
diopulmonary bypass has been advocated for circulatory support in moribund patients requiring angiography. Cardiac deterioration with the induction of anesthesia is frequent because of vasodilatation in the presence of a fixed CO. The mortality rate in embolectomy series has progressively declined from 57% in the 1960s to 26% in contemporary series. However, wide variability is reported (16 to 46%). With higher mortality rates (ie, ≥ 40%) reported in series with a predominance (ie, ≥ 50%) of cardiac arrest patients, Cardiac arrest is a recognized predictor of poor outcome, with an approximate mortality rate of 60%. IVC filter placement has been reported to be successful without systemic fibrinogenolysis or bleeding.

Special Considerations

Emboli-in-Transit

Right heart emboli-in-transit have been echocardiographically documented in up to 17% of patients with acute PEs. Given the widespread availability and increasing application of ECHO, it is likely that clinicians will be challenged increasingly to define their significance and treatment. The European Cooperative Study of 119 patients classified emboli-in-transit into two major categories with different morphologies, etiologies, and clinical significance. Type A thrombi are long, thin, extremely mobile, characteristically found in the RA, and originate in the peripheral deep venous system. In a large series of patients with massive PEs and cardiovascular instability, right heart emboli were detected in 18% of patients. Eighty-four percent of the emboli were in the RA and measured between 2 and 10 cm in 92% of cases, with prolapse into the RV in 83% of cases. Type-A patients were considered to comprise a high-risk group that was characterized by severe PEs of which one third were fatal within 24 h of the diagnosis. Overall, the rate of early mortality (ie, ≤ 8 days) was 44% and was uniformly related to PE. The mortality rate was ≥ 60% in patients who had been treated with anticoagulation therapy alone, 40% in those treated with thrombolysis, and 27% in those who were treated surgically, which led to the conclusion that the presence of type-A thrombi should be considered an absolute surgical emergency. Similar findings of association with severe PE, a proclivity to migrate to the PA (precipitating acute deterioration), a high mortality rate (ie, ≥ 50%) with medical management (ie, conservative, anticoagulation, and thrombolytic therapy) compared to surgical management (15%), and recommendations for emergency surgery have been reported in other large series. Type-B thrombi are usually smaller, are round or oval-shaped, are less mobile, and arise in the RV. They are commonly associated with known RV thrombogenetic abnormalities (ie, congestive heart failure, pacemaker electrodes, or cardiac foreign bodies) and resemble an LV thrombus. Although PE is reported to occur in 40% of these patients, it was never fatal and the prognosis was good, independent of treatment type. In contrast to the above, Kinnery and Wright conducted a meta-analysis of 119 case reports in which data were analyzed by multivariate logistic regression analysis in a treatment-received method. All types of thrombi were included in the analysis, and it was found that morphologic characteristics were not related to survival. The overall mortality rate was 31%, and there was no difference in the mortality rate between patients with attached thrombi (28%) and unattached thrombi (39%). Factors predicting survival in patients with right heart thrombi were the presence of PE and the treatment type. The probability for survival in patients with PEs treated with heparin therapy, thrombolytic agents, or surgical embolectomy or who had received no treatment was 0.70, 0.62, 0.62, and 0.19, respectively. The probability for survival in patients without PEs for the same treat-
ment groups was 0.92, 0.89, 0.89, and 0.53, respectively. The authors concluded that the efficacies of all three treatments were similar and suggested that heparin may be the best choice for stable patients. In a recent series of hemodynamically unstable patients with PE and right heart thrombus undergoing thrombolysis, continuous echocardiographic surveillance revealed a gradual reduction in echodensity and motility with final disappearance during or shortly after thrombolysis regardless of size or motility. No life-threatening events occurred during this period. Similar observations were reported over several days in stable patients who had been treated with heparin. Therefore, it appears that there is more conflict than consensus in the treatment of right heart thrombi and that the approach should be individualized.

Cardiac Arrest

Cardiac arrest will occur within 1 to 2 h after the onset of clinical presentation in two thirds of fatal PE cases, and acute PE/myocardial infarction report onset of clinical presentation in two thirds of fatal PE occur spontaneously, and is at least momentarily uniformly due to PEA, usually follows shock but may be the best choice for stable patients.

Isolated RV Dysfunction

RV dysfunction has long been recognized as a marker for poor outcome in patients with PE, especially in those with hemodynamic instability. RV dysfunction in hemodynamically stable patients has been identified as a predictor of worse outcome in most but not all studies and appears to be related to the presence of recurrent PEs. Recommendations supporting thrombolysis for hemodynamically stable patients with RV dysfunction justifies their inclusion into the MPE category. Insofar as approximately 50% of all patients with acute PEs have signs of RV dysfunction, there appears to be a subset of patients within this population with a mortality rate exceeding that for patients with normal RV function but substantially less than that for shock patients. It has been reported that 10% of hemodynamically stable patients with RV dysfunction will deteriorate into
shock with a 50% mortality rate attributed to those with recurrent PEs. Multivariate analysis revealed that advanced age, recent trauma or orthopedic treatment, and dizziness or a lower systolic BP on presentation were associated clinical variables.

Thrombolysis has been proposed to be of benefit in this group based on observations from two series, although other studies have reported a worse outcome. In the MAPPET, hemodynamically stable patients with RV dysfunction who were treated with thrombolysis compared to those treated with heparin had a lower mortality rate (4.7% vs 11.1%, respectively), a reduced rate of recurrent PE (7.7% vs 18.7%, respectively), and an increased frequency of major bleeding (21.9% vs 7.8%, respectively). This observational study should be interpreted with caution because the heparin group was older with a higher incidence of congestive heart failure and chronic pulmonary disease. A recent retrospective study of 128 consecutive hemodynamically stable patients with massive PEs and RV dysfunction compared treatment with thrombolysis vs treatment with heparin. Thrombolysis was associated with a significantly higher mortality (6.25% vs 0%, respectively), severe bleeding (9.4% vs 0%, respectively), and intracranial bleeding (4.7% vs 0%, respectively). Given that the vast majority of patients with hemodynamically stable PE and RV dysfunction survive, it is imperative to more precisely define the subset of patients with RV dysfunction who will benefit from thrombolysis, given the substantial cost and risk of bleeding associated with it. Recurrent PE against the background of RV dysfunction appears to be the mechanism for the worse outcome, and perhaps identification of patients with substantial residual DVT will be a discriminator. Unfortunately, randomized trials of thrombolytics have not been shown to significantly decrease the incidence of objectively confirmed recurrent PEs. Given the substantial cost and the risk of bleeding, the use of thrombolytic therapy in hemodynamically stable patients with RV dysfunction remains controversial.

**CONCLUSION**

MPE is dominated by the pathophysiology of the disease, which often defines outcome in the first golden hour. Similar to the golden hour of trauma or myocardial infarction, MPE demands expediency. A pathophysiologic approach to recognition, resuscitation, and treatment provides the greatest opportunity to optimally impact on this lethal disease.

ACKNOWLEDGMENT: The author gives sincere appreciation and gratitude to Doug Coursin, MD, for his review of the manuscript, and to Julie Wardwell for its preparation.

**References**

20. Hermann RE, Davis JH, Holden WD. Pulmonary embolism: a clinical and pathological study with emphasis on the...
24 Gorham LW. A study of pulmonary embolism: two the mechanism of death based on a clinical pathological investiga\ñon of 100 cases of massive and 255 cases of minor embolism of the pulmonary artery. Arch Intern Med 1961; 108:76–90
30 Smith GT, Dammin GJ, Dexter L. Postmortem arterio\ñographic studies of the human lung in pulmonary embolization. JAMA 1964; 185:143–151
34 Dalen JE, Dexter L. Diagnosis and management of massive pulmonary embolism. Dis Mon 1967:1–34
35 Urokinase Pulmonary Embolism Trial. Phase 1 results: a cooperative study. JAMA 1970; 214:2163–2172
38 McIntyre KM, Sasahara AA. Hemodynamic and ventricular responses to experimental pulmonary embolism. Am J Cardiol 1967; 20:3–9
40 Smith GT, Dammin GJ, Dexter L. Postmortem arteriographic studies of the human lung in pulmonary embolization. JAMA 1964; 185:143–151
44 Dalen JE, Dexter L. Diagnosis and management of massive pulmonary embolism. Dis Mon 1967:1–34
45 Urokinase Pulmonary Embolism Trial. Phase 1 results: a cooperative study. JAMA 1970; 214:2163–2172
52 Smith GT, Dammin GJ, Dexter L. Postmortem arteriographic studies of the human lung in pulmonary embolization. JAMA 1964; 185:143–151
53 Urokinase Pulmonary Embolism Trial. Phase 1 results: a cooperative study. JAMA 1970; 214:2163–2172
55 McIntyre KM, Sasahara AA. Hemodynamic and ventricular responses to pulmonary embolism. Prog Cardiovasc Dis 1974; 17:175–190
57 Stein M, Levy SE. Reflex and humoral responses to pulmonary embolism. Prog Cardiovasc Dis 1974; 17:167–174
58 Malik AB. Pulmonary microembolism. Physiol Rev 1983; 63:1114–1207
64 Jardin F, Dubourg O, Gueret P, et al. Quantitative two dimensional echocardiography in massive pulmonary embo-
80 Levy SE, Simmons DH. Redistribution of alveolar ventilation following pulmonary thromboembolism in the dog. J Appl Physiol 1974; 36:60–68
85 McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971; 28:288–294
92 McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974; 65:534–543
93 UKEP Study Research Group. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J 1987; 8:2–10
96 UKEP Study Research Group. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J 1987; 8:2–10
98 Urokinase-Streptokinase Embolism Trial. Phase 2 results: a cooperative study. JAMA 1974; 229:1606–1613
100 Stein PD. The history and physical examination in patients with no prior cardiopulmonary disease: pulmonary embolism. Baltimore, MD: Williams and Wilkins, 1996; 41–53
101 Stein PD. The history and physical examination in all patients irrespective of prior cardiopulmonary disease: pul- monary embolism. Baltimore, MD: Williams and Wilkins, 1996; 54–58
102 Miller GA, Hall RJ, Paneth M. Pulmonary embolectomty, heparin, and streptokinase: their place in the treatment of acute massive pulmonary embolism. Am Heart J 1977; 93:568–574
103 Stein PD, Henry JW. Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes. Chest 1997; 112:974–979
104 Stein PD, Willis PV III, DeMets DL. History and physical examination in acute pulmonary embolism in patients with- out preexisting cardiac or pulmonary disease. Am J Cardiol 1981; 47:218–233


186 Konstantinides S, Geibel A, Kasper W. Submassive and


204 Stein PD. Application of ventilation/perfusion lung scans in specific populations of patients. Semin Respir Crit Care Med 1996; 17:23–29


226 Torbicki A. Imaging venous thromboembolism with emphasis on ultrasound, chest CT, angiography and echocardiography. Thromb Haemost 1999; 82:907–912


244 Ghignone M, Girling L, Frewitt RM. Volume expansion vs. norepinephrine in treatment of low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984; 60:132–135


252 Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest 1997; 111:218–224


261 Hull RD, Raskob GE, Grant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157:2562–2568


277 Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial; the Bolus Alteplase Pulmonary Embolism Group. Chest 1994; 106:718–724


304 Kronik G. The European Cooperative Study on the clinical


308 Bottiger BW. Thrombolysis during cardiopulmonary resuscitation: Fibrinolysis Proteolysis 1997; 11(suppl):93–100


320 Goldhaber SZ. Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation 1997; 96:716–718

321 Hamel E, Pacouret G, Vincentelli D. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001; 120:120–125